The team at PeriphaGen consists of dedicated and creative scientists and technicians working together to develop the next generation of drugs for the treatment of neurological disorders.
MANAGEMENT
David Krisky, M.D., Ph.D.
Executive Board Member
Dr. Krisky is a pathologist and virologist with 20 years of experience and is an inventor of the core technologies of the NET platform. Prior to founding PeriphaGen Dr. Krisky was the Senior Director of Medical Science and Clinical Safety for Diamyd Incorporated and was responsible for the product development and clinical program for the NET platform, the clinical safety of Phase I and Phase II NET platform clinical trials, and the clinical safety of the global Phase III clinical trials of the Diamyd Type 1 Diabetes product. Dr. Krisky leads PeriphaGen clinical development of NET products for neuropathic pain, neuropathy, and neuronal regeneration as well the clinical trial design and implementation.
James Wechuck, Ph.D.
Executive Board Member
Dr. Wechuck is a biochemical engineer with 15 years of experience in recombinant protein production, viral vector manufacturing, and biologics testing. Prior to founding PeriphaGen Dr. Wechuck was the Senior Director of Manufacturing Development for Diamyd Incorporated and developed and advanced the proprietary cGMP manufacturing production, purification, and formulation methodologies for the Diamyd Type 1 Diabetes Drug Product and the current NET platform products. Dr. Wechuck has also led the Chemistry Manufacturing and Controls (CMC) regulatory elements for several investigational drug applications in US and Europe. Dr. Wechuck directs the development and advancement of CMC activities for PeriphaGen NET platform therapeutics.
James R. Goss, Ph.D.
Consultant, Neuroscience and Preclinical Development
Dr. Goss is a neuroscientist with 30 years of experience with broad, hands-on involvement with drug development in academia, biotech, pharmaceutical, and non-profits. He worked alongside Drs. Krisky and Wechuck in developing the NET platform and demonstrating its therapeutic effectiveness in numersous neurological disorders. Dr. Goss has overseen the preclinical development of gene therapy, biologic, pharmaceutical, and device-based therapeutics; he consults on PeriphaGen's preclinical activities in neuropathy, pain, and other neurological areas.
​